Posted on

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

Go to Source

By sf-admin